CD8A and systemic lupus erythematosus: In combination with dynamic network biomarker (DNB) score analysis, the study has identified disease‐progression associated CD8+CD27+CXCR3− T cell signatures, with great potential in accurately predicting the progression of SLE and in providing crucial guidance on clinical treatment options.